

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017) - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Bailey Clifford	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes medications (2017-2018) - Eli Lilly : diabetes medications (2017-2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Bailey Clifford	<ul style="list-style-type: none"> - Sanofi Aventis : diabetes medications (2017-2018) - Merck Sharp & Dohme : Diabetes medications (2017-2018) - Novo-Nordisk : diabetes medications (2017-2018) - Abbott : Libre (2017-2018) - Boehringer-Ingelheim : SGLT2 inhibitor (2017-2018)
Ceriello Antonio	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2017-2018) - Boehringer-Ingelheim : Diabetes (2017-2018) - Eli Lilly : Diabetes (2017-2018) - Janssen-Cilag : Diabetes (2017-2018) - Sanofi Aventis : Diabetes (2017-2018) - Berlin Chemie AG : Diabetes (2017-2018) - Takeda Pharmaceuticals : Diabetes (2017-2018) - Novo-Nordisk : Diabetes (2017-2018) - Elsevier : Diabetes (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Eli Lilly : Diabetes (2017-2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Cosentino Francesco	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Cardiovascular Disease (2017) - Astra Zeneca : Cardiovascular Disease (2017) - Pfizer : CVD and diabetes (2017) - European Foundation for the Study of Diabetes (EFSD) : reviewer for the EFSD and Sanofi Diabetes Research Programme in Macrovascular Complications Programme (2017) - Bristol Myers Squibb : Cardiovascular Disease (2017-2018) - Merck Sharp & Dohme : Cardiovascular Disease (2017-2018) - Novo-Nordisk : CVD and diabetes (2017-2018) - Boehringer-Ingelheim : Cardiovascular disease (2018) - Eli Lilly : Cardiovascular disease (2018) - Pfizer : Cardiovascular disease (2018) - Mundipharma : CVD and diabetes (2018)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Delgado Victoria	<ul style="list-style-type: none"> - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017) - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Federici Massimo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Advisory board on Diabetes (2017) - Merck Sharp & Dohme : Advisory Board on diabetes (2017) - Springer-Nature : editor fee for ACTA DIABETOLOGICA (2017) - Merck Sharp & Dohme : DPP4 inhibitors (2018) - Sanofi Aventis : PCSK9 inhibitor (2018)
Filippatos Gerasimos	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2017-2018) - Servier : Heart Failure (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : CKD (2017-2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Filipatos Gerasimos	<ul style="list-style-type: none"> - Vifor International : Heart failure (2017-2018) - Boehringer-Ingelheim : Heart failure, Diabetes (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Devices (2017-2018) - European Union : Heart Failure (2017-2018)
Grant Peter J	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Janssen-Cilag : Canagliflozin (2017) - Bayer AG : Compass trial (2017) - Synexus : Diabetes adviser (2017) - Sage Publishers : Editor, Diabetes and Vascular Disease Research (2017) - Merck Sharp & Dohme : Metformin (2017) - Bayer : anticoagulant therapies (2018) - Boehringer-Ingelheim : diabetes, Empagliflozin (2018) - Novartis : DPPIV inhibitor, saxagliptin (2018) - Synexus : Recruiting patients into clinical trials, adviser (2018)
Grobee Diederick E	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : advisory board (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Grobbee Diederick E	<ul style="list-style-type: none"> - Esperion : Steering ctt (2018) D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Esperion : clinical trial lipids (2018) 2- Other Positions of Influence 2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. <ul style="list-style-type: none"> - chief scientific officer Julius Clinical Research Ltd (2017) - chief scientific officer Julius Clinical Research Ltd (part-time) (2018)
Hansen Tina	Nothing to be declared (2017-2018)
Huikuri Heikki	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. <ul style="list-style-type: none"> - Sanofi Aventis : Eliquis (abixaban) (2017-2018)
Johansson Isabelle	Nothing to be declared (2017-2018)
Juni Peter	1- Financial Declaration D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017-2018) - Biotronik : Drug-eluting stents (2017-2018) - Biosensors International Group : Drug-eluting stents (2017-2018) - The Medicines Company : Thrombin inhibitors (2017-2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Juni Peter	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017) - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical. (2018)
Lettino Maddalena	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Antithrombotic agents, anticoagulants (2017) - Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2017) - Amgen : Lipid lowering drugs (2017) - Pfizer : Anticoagulants (2017-2018) - Bayer Healthcare : Antithrombotic agents, anticoagulants (2017-2018) - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (2017-2018) - Astra Zeneca : Antithrombotic agents, statins (2017-2018) - Daiichi Sankyo : Anticoagulants (2018)
Marx Nikolaus	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Vital : Anticoagulants (2017-2018) - Sanofi Aventis : CV, Diabetes, Lipids (2017-2018) - Astra Zeneca : Diabetes (2017-2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Marx Nikolaus	<ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes (2017-2018) - Lilly : Diabetes (2017-2018) - Merck Sharp & Dohme : Diabetes (2017-2018) - Novo-Nordisk : Diabetes (2017-2018) - Amgen : Lipids (2017-2018) - Bristol Myers Squibb : Diabetes (2018) - Kowa Research Institute : Lipides (2018) - Genfit SA : NASH (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Anticoagulants (2017-2018) - Deutsche Forschungsgemeinschaft : Arrhythmia (2017-2018) - European Union : Circadian Rhythm (2017-2018) - Boehringer-Ingelheim : Diabetes (2017-2018) - EASD : Diabetes (2017-2018) - BMBF - German Ministry of Research and Education / DFG - German Research Foundation : REsearch (2017-2018) - Merck Sharp & Dohme : Diabetes (2018)
Mellbin Linda	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : PCSK-9 inhibitors (2017) - Sanofi Aventis : PCSK-9 inhibitors (2017)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Mellbin Linda	<ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2017-2018) - Boehringer-Ingelheim : Diabetes (2017-2018) - Novo-Nordisk : diabetes (2017-2018) - Sanofi Aventis : Diabetes (2018) - Roche Pharma : Diabetes (2018) - Amgen : Lipidlowering (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo-Nordisk : Diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : Testosterone (2017) - Bayer AG : Coronary artery disease, testosterone (2018)
Ostgren Carl-Johan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Diabetes (2017) - Astra Zeneca : Diabetes (2017-2018) - Eli Lilly : Diabetes (2017-2018) - Sanofi Aventis : Diabetes (2017-2018) - Novo-Nordisk : Diabetes (2017-2018) - Boehringer-Ingelheim : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Rocca Bianca	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : Aspirin, Rivaroxaban (2017) - Bayer AG : Xarelto (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - Italian Medicines Agency (AIFA) : aspirin (2017) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - NA (2017)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2017-2018) - Medtronic : Stents (2017-2018) - Biotronik : stents (2017-2018) - Terumo Inc : stents (2017-2018) - Abbott Vascular : stents (2017-2018)
Sattar Naveed	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : GLP-1 receptor agonist (2017) - Novo-Nordisk : GLP-1 receptor agonist (2017)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Sattar Naveed	<ul style="list-style-type: none"> - Amgen : PCSK9 (2017) - Sanofi Aventis : PCSK9 (2017) - Boehringer-Ingelheim : SGLT2 inhibitor (2017) - Eli Lilly : SGLT2 inhibitor (2017) - Janssen-Cilag : SGLT2 inhibitor (2017) - Astra Zeneca : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Eli Lilly : diabetes (2018) - Novo-Nordisk : diabetes (2018) - Napp Pharmaceuticals : diabetes (2018) - Amgen : lipids (2018) - Sanofi Aventis : lipids and diabetes (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabetes (2018) - Eli Lilly : diabetes (2018) - Sanofi Aventis : diabetes (2018) - Amgen : lipids (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : SGLT2 inhibitor (2017) - Boehringer-Ingelheim : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Seferovic Petar	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : coronary disease, heart failure (2017-2018) - Boehringer-Ingelheim : heart failure, hypertension (2017-2018) - Pfizer : heart failure, hypertension (2017-2018) - Berlin Chemie AG : heart failure, hypertension (2017-2018) - Astra Zeneca : heart failure (2018) - Novartis : heart failure, diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2017-2018) - Fondazione Internazionale Menarini : heart failure, diabetes (2018)
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Surgical Valves (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Valensi Paul	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Diabetes (2017) - Astra Zeneca : Diabetes (2017) - Sanofi Aventis : Diabetes (2017) - Lilly : Diabetes (2017) - Merck Sharp & Dohme : Diabetes (2017) - Novo-Nordisk : Diabetes (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2018) - Sanofi Aventis : Diabetes (2018) - Lilly : Diabetes (2018) - Abbott Laboratories : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Diabetes (2018) - Novo-Nordisk : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Wheeler David Collins	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Amgen : Cinacalcet (2017-2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Astra Zeneca : Cardiometabolic (2017-2018)</p> <p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY. - Boehringer-Ingelheim : daibetes (2017) - Boehringer-Ingelheim : Diabetes (2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Janssen-Cilag : daibetes (2017) - GlaxoSmithKline : Anaemia (2017-2018) - Vifor International : CKD (2017-2018) - Janssen-Cilag : Diabetes (2018) - MSD : Diabetes (2018) - Mundipharma : Diabetes (2018) - NAPP : Diabetes (2018)</p>

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Abilova Saamai	Nothing to be declared (2018)
Adamopoulos Stamatis	1- Financial Declaration B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Honorarium from Servier : Heart Failure (2018) - Honorarium from Novartis : Heart Failure (2018)
Ajjan Ramzi	1- Financial Declaration B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Abbott : Glucose meters (2018) - Boehringer-Ingelheim : hypoglycaemic agents (2018) - Eli Lilly : hypoglycaemic agents (2018) - Novo-Nordisk : Hypoglycaemic agents including insulin (2018) D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Abbott : Glucose meters (2018)
Alami Mohamed	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Astra Zeneca : Hypercholesterolemia (2018) - Pfizer : Hypercholesterolemia (2018) - Novartis : Hypertension (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Alami Mohamed	- Sanofi Aventis : Hypertension (2018)
Aronson Doron	Nothing to be declared (2018)
Avogaro Angelo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Novartis : Diabetes (2018) - Servier : Diabetes (2018) - Sanofi Aventis : Diabetes (2018) - Lilly : Diabetes (2018) - Takeda Pharmaceuticals : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) - Novo-Nordisk : Diabetes (2018) - Bayer AG : Diabetes (2018) - Bruno : Diabetes (2018) - Amgen : Lipid (2018) - GlaxoSmithKline : Vaccines (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Baigent Colin	1- Financial Declaration D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Boehringer-Ingelheim : Empagliflozin (2018) - Novartis : Sacubitril (2018) - Pfizer : Sirolimus (2018)
Banu Cristiana	Nothing to be declared (2018)
Benlamin Hisham	Nothing to be declared (2018)
Birkeland Kare	1- Financial Declaration B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Astra Zeneca : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) - Novo-Nordisk : Diabetes (2018) - Roche Diagnostics : Diabetes (2018) C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY. - Fagbokforlaget : Internal Medicine (2018)
Bosevski Marijan	Nothing to be declared (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Boskovic Aneta	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension (2018) - Sanofi Aventis : PTE (2018)
Brodmann Marianne	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulation (2018) - Daiichi Sankyo : Anticoagulation (2018) - Intact Vascular : Medical Devices (2018) - Abbott : Medical Devices (2018) - Medtronic : Medical Devices (2018) - Biotronik : Medical Devices (2018) - BD BARD : Medical Devices (2018) - Philips Spectranetics : Medical Devices (2018) - Soundbite : Medical Devices (2018)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Apixaban (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2018) - Bayer : Aspirin, rivaroxaban (2018) - Novartis : Canakinumab (2018) - MEDSCAPE-the heart.org : Inespecific (2018) - Astra Zeneca : Ticagrelor (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2018) - Novartis : LCZ696 (PROMISE trial / PERSPECTIVE trial) (2018) - Astra Zeneca : Ticagrelor (EPICOR Study, THEMIS trial) (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Vice-president elect. Spanish Society of Cardiology (Will become VP in October 2019) FAHA (2018)
Ceconi Claudio	Nothing to be declared (2018)
Chioncel Ovidiu	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Philips : Echocardiographic (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2018) - Servier : Heart Failure (2018) - Vifor International : Heart Failure (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Chowdhury Tahseen	Nothing to be declared (2018)
Coats Andrew	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Faraday Australia : Acute MI (2018) - Bayer AG (event review committee member) : CV disease (2018) - Novartis : Heart Failure (2018) - Servier : Heart Failure (2018) - Menarini : Heart Failure (2018) - Astra Zeneca : Hyperkalaemia (2018) - Vifor International : Iron deficiency (2018) - Nutricia : Nutrition (2018) - WL Gore : Prosthetic Valves (2018) - Respicardia : Sleep Apnoea (2018)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : TICAGRELOR (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2018) - Medtronic : COREVALVE (2018)
Collins Peter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Menarini : Stable ischaemic heart disease (2018)
Cosyns Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : DOACS (2018) - Pfizer : Dyslipidemia (2018) - Abbott : Prosthetic valves (2018) - Medtronic : Prosthetic valves (2018) <p>C - RECEIPT OF ROYALTIES FOR INTELLECTUAL PROPERTY.</p> <ul style="list-style-type: none"> - Oxford University Press : Echocardiography (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - HeartFlow : Coronary disease (2018)
David Lilia	<p>Nothing to be declared (2018)</p>

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Deljanin Ilic Marina	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Berlin Chemie AG : Nebivolol and Lercanil in the treatment of Arterial Hypertension (2018) - Novartis : Sacubitril/Valsartan in patients with Heart Failure with reduced ejection fraction (2018) - Astra Zeneca : Ticagrelor in Acute Coronary Syndrom (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Resverologix Corp. : BET on Mace Study; to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major adverse cardiovascular events. (2018)
Di Lenarda Andrea	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2018) - Vifor International : Heart Failure (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Past President of italian Association of Italian Cardiologists (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Di Mario Carlo	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Volcano : Interventional Cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Interventional Cardiology (2018) - Shockwave : Interventional Cardiology (2018) - Daiichi Sankyo : TAVI (2018) - Edwards Lifesciences : TAVI (2018)
Fabryova Lubomira	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2018) - Amgen : evolocumab (2018) - MSD : ezetimib, sitagliptin (2018) - Kowa : pemafibrate (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : PI/dapagliflozin (2018) - Kowa : PI/pemafibrate (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Fisher Miles	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - NAPP : diabetes / canagliflozin (2018) - Astra Zeneca : diabetes / dapagliflozin (2018) - Eli Lilly : diabetes / dulaglutide (2018) - Boehringer-Ingelheim : diabetes / empagliflozin (2018) - Novo-Nordisk : diabetes / liraglutide / semaglutide (2018) - Sanofi Aventis : diabetes / Toujeo (2018)
Fitzsimons Donna	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medscape : Heart failure (2018)
Fras Zlatko	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : anticoagulation therapy (2018) - Pfizer : anticoagulation therapy (2018) - Astra Zeneca : antiplatelet therapy (2018) - Boehringer-Ingelheim : cardiometabolism (2018) - Novo-Nordisk : cardiometabolism (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Fras Zlatko	<ul style="list-style-type: none"> - Servier : general cardiology (2018) - Krka Pharma : hypertension, lipids (2018) - Amgen : lipid treatment (2018) - Sanofi Aventis : lipid treatment (2018)
Gavina Cristina	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : Dapagliflozin (2018) - Daiichi Sankyo : Edoxaban (2018) - Boehringer-Ingelheim : Empagliflozin (2018) - Amgen : Evolocumab (2018) - Bayer : Rivaroxaban (2018)
Gruev Ivan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : arterial hypertension (2018) - Berlin Chemie AG : arterial hypertension (2018) - Actavis : arterial hypertension (2018) - Mylan : arterial hypertension (2018) - Merck Germany : arterial hypertension (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gruev Ivan	<ul style="list-style-type: none"> - Egis Pharma : arterial hypertension, hyperuricemia (2018) - Pfizer : atrial fibrillation (2018) - Bayer : Atrial fibrillation, heart failure (2018) - Astra Zeneca : diabetes and CVD, CAD (2018) - Sanofi Aventis : dislipidemia (2018) - Esperion : dislipidemia (2018) - Novartis : heart failure (2018) - Amgen : heart failure, dislipidemia (2018) - Bulgarian football union : sports cardiology (2018)
Halvorsen Sigrun	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotic treatment (2018) - Astra Zeneca : Anti-thrombotic treatment (2018) - Boehringer-Ingelheim : Anti-thrombotic treatment (2018) - Pfizer : Anti-thrombotic treatment (2018) - Bayer AS : Anti-thrombotic treatment (2018) - Sanofi Aventis : Cholesterol lowering treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hansen Dominique	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Johnson & Johnson : Bariatric surgery: advice and development of patient brochure (only in 2018, no additional activities afterwards) (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Johnson & Johnson : Lectures (2018)</p>
HASAN ALI Hosam	<p>Nothing to be declared (2018)</p>
Hildebrandt Per	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Astra Zeneca : diabetes treatment (2018) - Novartis : Heart failure (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Thrombosis Research Institute : anti-coagulation treatment of atrial fibrillation (2018)</p>

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hoes Arno	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <p style="padding-left: 20px;">- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2018)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <p style="padding-left: 20px;">- Member of the Health Council of the Netherlands (advisory board to the Ministry of Health) (2018)</p>
Holt Richard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Antipsychotics (2018) - Lundbeck : Antipsychotics (2018) - Sunovion : Antipsychotics (2018) - Astra Zeneca : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Eli Lilly : Diabetes (2018) - Janssen-Cilag : Diabetes (2018) - Sanofi Aventis : Diabetes (2018) - Novo-Nordisk : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Holt Richard	<ul style="list-style-type: none"> - Mylan : Diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo-Nordisk : Diabetes (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Editor of Diabetic Medicine (2018)
Home Philip	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes (2018) - Novo Nordisk : Diabetes (2018) - MedImmune : Diabetes (2018) - Astrazeneca : Diabetes (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - GlaxoSmithKline : Diabetes (2018) - Janssen : Diabetes (2018) - Sanofi : Diabetes (2018) - Merck Inc (MSD) : Diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Merck Inc (MSD) : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Home Philip	E - RESEARCH FUNDING (PERSONAL). - GlaxoSmithKline : Diabetes (2018) - Sanofi : Diabetes (2018)
Ibrahimi Pranvera	Nothing to be declared (2018)
Jahangirov Tofiq	Nothing to be declared (2018)
Janion Marianna	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boehringer-Ingelheim : dabigatran (2018) - Adamed : ezetimibe (2018) - Servier : perindopril (2018) B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Egis Pharma : allopurinol (2018) - Pfizer : rivaroxaban (2018) - Novartis : sakubitril (2018)
Jimenez Navarro Manuel Francisco	Nothing to be declared (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants (2018) - Bayer Vital : Anticoagulants (2018) - Astrazeneca : Antiplatelet (2018) - Roche Diagnosticsker : Biomar (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Roche Diagnosticsarker : Biomarker (2018) - Daiichi Sankyo : Xarelto (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - President of the German Society of Cardiology (2018)
Khunti Kamlesh	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Diabetes (2018) - Astra Zeneca : Diabetes (2018) - Bayer : Diabetes (2018) - Novartis : Diabetes (2018) - Servier : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Khunti Kamlesh	<ul style="list-style-type: none"> - Sanofi Aventis : Diabetes (2018) - Lilly : Diabetes (2018) - Berlin Chemie AG : Diabetes (2018) - Roche Pharma : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) - Novo-Nordisk : Diabetes (2018) - NAPP : Diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Novartis : Diabetes (2018) - Pfizer : Diabetes (2018) - Sanofi Aventis : Diabetes (2018) - Lilly : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) - Novo-Nordisk : Diabetes (2018)
Komajda Michel	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : cardio metabolic (2018) - Merck Sharp & Dohme : Cardio metabolic (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Komajda Michel	<ul style="list-style-type: none"> - Novartis : Heart failure (2018) - Servier : Heart failure (2018) - Sanofi Aventis : Heart failure /metabolism (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - President Fondation Cœur et Recherche. A not for profit organisation funding cardio vascular research(volunteer position). (2018)
Kurashvili Ramaz	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo Nordisk : Diabetology (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - AstraZeneka : Diabetology (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - Founder and owner of the National Center for Diabetes Research (2018)
Lambrinou Ekaterini	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Health Policy Partnership : HF Policy Network Handbook Launch (2018) - Bayer AG : Honorarium (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lambrinou Ekaterini	<ul style="list-style-type: none"> - TRAMA SOLUTIONS : Online course speaker fees (2018) - Novartis : Speaker fee and honorarium (2018)
Landmesser Ulf	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Advisory Board fees (2018) - Medicines Company : Advisory Board fees (2018) - Amgen : Speaker fees (2018) - Sanofi Aventis : Speaker fees (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : Research Grant (2018)
Lazareva Irina	Nothing to be declared (2018)
Lehmann Roger	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Eli Lilly : Diabetes (2018) - Sanofi Aventis : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lehmann Roger	- Novo-Nordisk : Diabetes (2018)
Lehto Seppo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo-Nordisk : Diabetes (2018) - Amgen, Sanofi : Lipids (PCSK-9) (2018)
Lengyel Csaba	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetology (2018) - Eli Lilly : Diabetology (2018) - Novartis : Diabetology (2018) - Sanofi Aventis : Diabetology (2018) - Novo-Nordisk : Diabetology (2018) - Roche Diagnostics : Diabetology (2018) - Krka Pharma : Diabetology (2018) - Di-Care : Diabetology (2018) - Elektronika 77 : Diabetology (2018) - Boehringer-Ingelheim : Diabetology, Cardiovascular diseases (2018) - Egis Pharma : Diabetology, Cardiovascular diseases (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lengyel Csaba	E - RESEARCH FUNDING (PERSONAL). - Astra Zeneca : Diabetology (2018)
Lewis Basil S	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Pfizer : Antithrombotics (2018) - Astra Zeneca : Diabetes (2018) - Merck Sharp & Dohme : Heart failure (2018) - CSL Behring : Lipidology, Secondary prevention (2018) B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Astrazeneca : Antithrombotics (2018) - Astra Zeneca : Diabetes (2018) - Pfizer : Diabetes (2018) - Merck Sharp & Dohme : Heart failure (2018) - Kowa : Lipidology (2018) - Resverlogix : Lipidology. secondary prevention (2018)
Liem An Ho	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Amgen Inc : cholesterol lowering medication (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Liem An Ho	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : prevention (2018)
Linde Cecilia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : CRT heart failure (2018) - Impulse Dynamics : device therapy (2018) - Medtronic Foundation : device therapy (2018) - Novartis : honoraria for speaking at cardiology highlights for HFA Athens (2018) - Bayer : honoraria for speaking at cardiology update 2018 to 2019 for swedish cardiologists (2018) - Vifor International : iron therapy for heart failure (2018) - Liva Nova : medical device (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : CRT heart failure (2018)
Linhart Ales	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension, coronary heart disease, heart failure (2018) - Boehringer-Ingelheim : Aterial fibrillation, diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Linhart Ales	<ul style="list-style-type: none"> - Sanofi Aventis : Fabry disease (2018) - Shire HGT : Fabry disease (2018) - Novartis : Heart failure (2018)
Lorusso Roberto	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : Cardiac Valve Prostheses - Extracorporeal Circulation Technology (2018) - Medtronic Foundation : Cardiovascular Diseases and treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : Cardiac Valve Prostheses - Extracorporeal Circulation Technology (2018)
Mach Francois	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Lipid lowering (2018) - Amgen Inc : Lipid lowering (2018) - MSD : Lipid Lowering (2018)
Magri Caroline Jane	<p>Nothing to be declared (2018)</p>
Mancini Tatiana	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Mansourati Jacques	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sorin Group : HONORARIA, CONSULTANCY, INVESTIGATOR (2018) - Medtronic : HONORARIA, INVESTIGATOR (2018) - Abbott : Investigator (2018) - St Jude Medical : INVESTIGATOR (2018) - Boston Scientific : SPEAKER FEES, HONORARIA, INVESTIGATOR (2018) - Amgen : SPEAKER FEES, INVESTIGATOR (2018) - Sanofi Aventis : SPEAKER FEES, INVESTIGATOR (2018) - MSD : SPEAKER FEES, INVESTIGATOR (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : Grant (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Pacemaker monitoring (2018)
Marandi Toomas	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : NA (2018) - Sanofi Aventis : NA (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Marandi Toomas	- Berlin chemie menarini : NA (2018)
Milicic Davor	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo-Nordisk : Antidiabetic medications (2018) - Abbott : LVAD (2018) - Pfizer : NOACS (2018) - Bayer Healthcare : NOACS (2018) - Boehringer-Ingelheim : NOACS, SGLT-2 inhibitors (2018) - Amgen : PCSK9 inhibitors (2018) - Sanofi Aventis : PCSK9 inhibitors (2018) - Novartis : sacubitril valsartan (2018)
Mourali Mohamed Sami	Nothing to be declared (2018)
Mueller Christian Eugen	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antidiabetics (2018) - Indorsia : Antiplatelet therapy (2018) - Roche Diagnostics : Diagnostics (2018) - Sanofi Aventis : Lipid lowering (2018) - Amgen : Lipid-lowering (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics (2018) - OrthoClinical Diagnostics : Diagnostics (2018) - Singulex : Diagnostics (2018) - Abbott Laboratories : Diagnostics (2018) - Roche Diagnostics : Diagnostics (2018) - Siemens : Diagnostics (2018) - Sphingotec : Diagnostics (2018) - quidel : Diagnostics (2018)
Naser Nabil	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Tritace - Ramipril (2018) - Novartis : Uperio - Valsartan - Sacubitril (2018)
Nedogoda Sergey	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Pulmonary Hypertension, Atrial Fibrillation (2018) - Gedeon Richter : Arterail Hypertension (2018) - Servier : Arterial Hypertension (2018) - Takeda Pharmaceuticals : Arterial Hypertension (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Nedogoda Sergey	<ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2018) - Merck Sharp & Dohme : Diabetes (2018) - Astra Zeneca : Diabetes, ACS (2018) - Sanofi Aventis : Diabetes, Arterial hypertension, Lipids (2018) - Boehringer-Ingelheim : Diabetes, Atrial Fibrillation (2018) - Novartis : Heart failure (2018) - Amgen : Lipids (2018) - Abbott : Lipids, Arterial Hypertension (2018)
Nesukay Elena	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : cardiology (2018)
Neumann Franz Josef	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Anticoagulant Therapy (2018) - Daiichi Sankyo : Anticoagulant therapy (2018) - Pfizer : Anticoagulant therapy (2018) - Bayer Healthcare : Anticoagulant therapy (2018) - Bristol Myers Squibb : Anticoagulant therapy (2018) - Boston Scientific : Interventional cardiology (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Neumann Franz Josef	<ul style="list-style-type: none"> - Biotronik : Interventional Cardiology (2018) - Edwards Lifesciences : Transcatheter valves (2018) - Medtronic : Transcatheter valves (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulant therapy (2018) - Pfizer : Anticoagulation (2018) - GlaxoSmithKline : Anticoagulation (2018) - Novartis : Heart failure (2018) - Biotronik : Interventional Cardiology (2018) - Abbott Vascular : MitraClip, Xience Stent (2018) - Boston Scientific : Stents (2018) - Edwards Lifesciences : Transcatheter Valves (2018) - Medtronic : Transcatheter Valves (2018)
Norhammar Anna	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, Eli Lilly, MSD Sweden : Diabetes (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - 1. Member of SWEDEHEART-registry working groups; SEPHIA and Preventive Cardiology 2. Advisory expert to, and applicant reviewer to, Swedish Heart and Lung Foundation (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Persson Frederik	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Diabetes (2018) - Astra Zeneca : Diabetes (2018) - Bayer : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Novartis : Diabetes (2018) - Abbott Laboratories : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) - Novo-Nordisk : Diabetes (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2018)
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2018) - Servier : Heart failure (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Percutaneous Aortic and Mitral treatment (2018) - Medtronic : Percutaneous Aortic and mitral treatment (2018) - Abbott : Percutaneous Mitral treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research (2018)
Petrou Petros M	<p>Nothing to be declared (2018)</p>
Petruioniene Zaneta	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Arterial Hypertension (2018) - Berlin Chemie AG : Arterial hypertension (2018) - Servier : Arterial hypertension and dyslipidemia (2018) - Mylan : Arterial Hypertension and Dyslipidemia (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petrulioniene Zaneta	<ul style="list-style-type: none"> - Pfizer : Dyslipidemia (2018) - Krka Pharma : Dyslipidemia (2018)
Piepoli Massimo Francesco	Nothing to be declared (2018)
Raissova Aigul	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : diabet (2018) - Novo-Nordisk : diabet (2018) - Promed : nafld (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Promed : NAFLD (2018)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : aortic stenosis (2018) - Menarini : CAD- hypertension (2018) - Unipharma : hypertension-thrombosis (2018) - Abbott : lipids (2018) - Amgen : lipids (2018) - Servier : LIPIDS (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Sanofi Aventis : Lipids (2018) - Lilly : Lipids (2018) - Unilever : lipids (2018) - Merck Sharp & Dohme : lipids (2018) - Vianex : lipids (2018) - RAFARM : LIPIDS (2018) - ELPEN : LIPIDS-THROMBOSIS (2018) - Bayer Healthcare : Thrombosis (2018) - Leo Pharma : THROMBOSIS (2018) - NovaGEM CYPRUS : THROMBOSIS (2018)
Rosano Giuseppe M C	<p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - Shareholder of GC Mavel and Linuk Ltd - both companies provide consultancies for patient care and centralised assessments of non-invasive tests (2018) <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Member of CVWP at the European Medicines Agency Member of European Assessment Board at AIFA (Italian Drug Agency) Member of the Assessment Board at Malta Healthcare Agency (2018)
Rossing Peter	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes (2018) - Boehringer-Ingelheim : diabetes (2018) - Eli Lilly : diabetes (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Rossing Peter	<ul style="list-style-type: none"> - Sanofi Aventis : diabetes (2018) - Bayer Healthcare : diabetes (2018) - Astellas : diabetes (2018) - Novo-Nordisk : diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes (2018) - Novo-Nordisk : diabetes (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - OTHER - Novo Nordisk A/S (2018)
Ryden Lars	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Advisory Board and lectures (2018) - Merck Sharp & Dohme : Cardiology; Course organisation, lecture (2018) - Bayer : Diabetes and cardiovascular disease (2018) - Boehringer Ingelheim Pharma GmbH & Co. KG : Diabetes and cardiovascular disease. Expert committee work. (2018) - Novo Nordisk : Diabetes and cardiovascular disease. Lectures and expert committee work. (2018) - Astrazeneca : Pharma (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Pharma (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ryden Lars	<ul style="list-style-type: none"> - Bayer : Pharma (2018) - Merck Sharp & Dohme : Pharma (2018) - Novo-Nordisk : Pharma (2018) - Boehringer Ingelheim : Pharma (2018)
Saadeh Georges	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : speaker fees (2018) - Boehringer-Ingelheim : speaker fees (2018) - Novartis : speaker fees (2018) - Pfizer : speaker fees (2018)
Scherr Daniel	<p>Nothing to be declared (2018)</p>
Shivalkar Bharati	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bracco Pharmaceutical : ultrasound contrast (2018)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<ul style="list-style-type: none"> - Novartis : Arterial Hypertension, Heart Failure (2018) - Merck Sharp & Dohme : Atherosclerosis (2018) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2018) - Pfizer : General Cardiology (2018)
Siasos Gerasimos	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes (2018)
Simpson Iain A	<p>Nothing to be declared (2018)</p>
Svingen Gard Frodahl Tveitevaag	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Speaker fee (2018) - Sanofi Aventis : Speaker fee (2018) - Novo-Nordisk : Speaker fee (2018)
Thrainsdottir Inga Sigurros	<p>Nothing to be declared (2018)</p>
Touyz Rhian	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : antihypertensive drugs (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Touyz Rhian	<ul style="list-style-type: none"> - Alynlam : antihypertensive drugs (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - British Heart Foundation : Hypertension research (2018) - Medical Research Council, UK : Hypertension research (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American Heart Association International Society of Hypertension British Irish Hypertension Society (2018)
Trusinskis Karlis	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : dabigatran, empagliflozin (2018) - Novo-Nordisk : liraglutide (2018) - Berlin Menarini : olmesartan, nebivolol (2018) - Biotronik : orsiro, magmaris (2018) - Servier : perindopril, drug single pill combinations (2018) - Bayer : rivaroxabane (2018) - Astra Zeneca : Ticagrelor, dapagliflozin (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : bisoprolol (2018) - Bayer : rivaroxabane (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ural Dilek	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab (2018) - Merck Sharp & Dohme : Ezetimibe (2018)
Vinereanu Dragos	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Acute Coronary Syndromes, Diabetes (2018) - Boehringer-Ingelheim : Atrial Fibrillation (2018) - Pfizer : Atrial Fibrillation (2018) - Novartis : Cardiovascular prevention, Heart Failure (2018) - Servier : Hypertension, Heart Failure (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Johnson & Johnson : Clinical trial (2018) - Quintiles : Clinical trial (2018) - PPD Global : Clinical trial (2018) - Chiltern : Clinical trial (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - Johnson & Johnson : Clinical trial (2018) - Quintiles : Clinical trial (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Vinereanu Dragos	<ul style="list-style-type: none"> - PPD Global : Clinical trial (2018) - Dalcor : Clinical trial (2018) - Chiltern : Clinical trial (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Vice-rector of the University; President of the Romanian Society of Cardiology. (2018)
Wijns William	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Microport : device (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Co-Director of EuroPCR, the official annual meeting of EAPCI, since May 2010. Chairman of PCR, since May 2012. Co-Director of PCR Africa, since February 2013. Scientific cardiology advisor Rede Optimus Research. Co-founder of Argonauts Partners (innovation accelerator). (2018)
Wilhelm Matthias	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : CV drugs (2018) - Astra Zeneca : CV drugs (2018) - Novartis : CV drugs (2018) - Servier : CV drugs (2018) - Sanofi Aventis : CV drugs (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Wilhelm Matthias	<ul style="list-style-type: none"> - Vifor International : CV drugs (2018) - Bristol Myers Squibb : CV drugs (2018) - Merck Sharp & Dohme : CV drugs (2018) - Novo-Nordisk : CV drugs (2018) - Pfizer : CV drug (2018) - Bristol Myers Squibb : CV drug (2018) - Ergoline : Ergometer & ECG Monitoring (2018) - Spirig Health Care : Pulmo drugs (2018)
Williams Bryan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Hypertension (2018) - Daiichi Sankyo : Hypertension (2018) - Novartis : Hypertension (2018) - Servier : Hypertension (2018) - Vascular Dynamics Inc, USA : Hypertension - device based therapy (2018) - Pfizer : Hypertension and cardiovascular risk management (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Vascular Dynamics Inc USA : Mobius HD device for baroreceptor amplification in resistant hypertension (2018)

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Williams Bryan	2- Other Positions of Influence 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Trustee of BP UK - a patient's association (2018)
Zelveian Parounak	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Takeda Pharmaceuticals : Hypertension (2018) - Egis Pharma : Hypertension & IHD (2018) - Recordati International : Hypertension & IHD (2018) - Krka Pharma : Hypertension & IHD (2018) - Grindex Pharma : Hypertension & IHD (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017) - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Baigent Colin	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Empagliflozin (2017-2018) - Novartis : Sacubitril (2017-2018) - Pfizer : Sirolimus (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : TICAGRELOR (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb : apixaban (2018) - Medtronic : COREVALVE (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017) - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Fitzsimons Donna	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medscape : Heart failure (2018)
Gale Christopher Peter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : ACS, heart failure (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<ul style="list-style-type: none"> - Vifor Pharma : Heart failure (2017) - Novartis : heart failure, CVD (2017) - Astra Zeneca : ACS (2018) - Novartis : coronary artery disease (2018) - Bayer : coronary artery disease, AF (2018) - Vifor International : heart failure (2018) - Menarini : ischaemic heart disease (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixiban, AF (2018)
Grobbee Diederick E	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : advisory board (2018) - Esperion : Steering ctt (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Esperion : clinical trial lipids (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - chief scientific officer Julius Clinical Research Ltd (2017) - chief scientific officer Julius Clinical Research Ltd (part-time) (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotic treatment (2017-2018) - Astra Zeneca : Anti-thrombotic treatment (2017-2018) - Boehringer-Ingelheim : Anti-thrombotic treatment (2017-2018) - Pfizer : Anti-thrombotic treatment (2017-2018) - Bayer AS : Anti-thrombotic treatment (2017-2018) - Sanofi Aventis : Cholesterol lowering treatment (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017-2018)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2017-2018) - Biosense Webster : Pacemaker, Ablation (2017-2018) - Biotronik : Pacemaker, catheter (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017) - Biosense Webster : Electrophysiology, arrhythmias (2018) - Abbott : Electrophysiology, arrhythmias (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017-2018)
lung Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure drugs (2017) - Boehringer Ingelheim : Anticoagulants (2017-2018) - Edwards Lifesciences : Heart valve prostheses (2017-2018)
Juni Peter	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017-2018) - Biotronik : Drug-eluting stents (2017-2018) - Biosensors International Group : Drug-eluting stents (2017-2018) - The Medicines Company : Thrombin inhibitors (2017-2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017) - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical. (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2017) - Astra Zeneca : Ticagrelor (2017) - Bayer Vital : Xarelto-NOAK (2017) - Daiichi Sankyo : Anticoagulants (2018) - Bayer Vital : Anticoagulants (2018) - Astrazeneca : Antiplatelet (2018) - Roche Diagnosticsker : Biomar (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2017) - Philips : MRT (2017) - Roche Diagnosticsarker : Biomarker (2018) - Daiichi Sankyo : Xarelto (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - President of the German Society of Cardiology (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Advisory Board fees (2017-2018) - Medicines Company : Advisory Board fees (2017-2018) - Amgen : Speaker fees (2017-2018) - Sanofi Aventis : Speaker fees (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : Research Grant (2017-2018)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : devices (2017) - Abbott : devices (2017-2018) - Boston Scientific : devices (2017-2018) - Medtronic : devices (2017-2018) - Biotronik : devices (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Leclercq Christophe	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
Lettino Maddalena	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Antithrombotic agents, anticoagulants (2017) - Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2017) - Amgen : Lipid lowering drugs (2017) - Pfizer : Anticoagulants (2017-2018) - Bayer Healthcare : Antithrombotic agents, anticoagulants (2017-2018) - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (2017-2018) - Astra Zeneca : Antithrombotic agents, statins (2017-2018) - Daiichi Sankyo : Anticoagulants (2018)
Lewis Basil S	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Astra Zeneca : Diabetes (2018) - CSL Behring : Lipidology, Secondary prevention (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017) - Pfizer : Lipidology (2017) - Astrazeneca : Antithrombotics (2017-2018) - Astra Zeneca : Diabetes (2017-2018) - Pfizer : Diabetes (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Kowa : Lipidology (2017-2018) - Resverlogix : Lipidology. secondary prevention (2018)
Merkely Bela	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : ACS (2017) - Medtronic : CRT course (2017-2018) - Abbott : CRT/ICD (2017-2018) - Biotronik : ICD/CRT (2017-2018) - Astra Zeneca : HF (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : cardiac rhythm management (2017) - Medtronic : cardiac rhythm management (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Merkely Bela	- Boston Scientific : CRT (2017-2018)
Mueller Christian Eugen	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Antihypertensive (2017) - Siemens Healthcare : Diagnostics (2017) - Singulex : Diagnostics (2017) - Boehringer-Ingelheim : Antidiabetics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Sanofi Aventis : Lipid lowering (2017-2018) - Indorsia : Antiplatelet therapy (2018) - Amgen : Lipid-lowering (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics (2017-2018) - OrthoClinical Diagnostics : Diagnostics (2017-2018) - Singulex : Diagnostics (2017-2018) - Abbott Laboratories : Diagnostics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Siemens : Diagnostics (2017-2018) - Sphingotec : Diagnostics (2017-2018) - quidel : Diagnostics (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2017-2018) - Servier : Heart failure (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING (2017) - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : MitraClip (2017) - Boston Scientific : TAVI (2017) - Medtronic : TAVI (2017) - Boston Scientific : Percutaneous Aortic and Mitral treatment (2018) - Medtronic : Percutaneous Aortic and mitral treatment (2018) - Abbott : Percutaneous Mitral treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Priori Silvia Giuliana	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boston Scientific : Cardiac device (2017-2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Audentes Rx : Gene therapy (2017-2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Takeda Pharmaceuticals : antiarrhythmic drugs (2017-2018)</p>
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017) - Edwards Lifesciences : aortic stenosis (2017-2018) - Menarini : CAD- hypertension (2017-2018) - Unipharma : hypertension-thrombosis (2017-2018) - Abbott : lipids (2017-2018) - Amgen : lipids (2017-2018)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Sanofi Aventis : Lipids (2017-2018) - Lilly : Lipids (2017-2018) - Unilever : lipids (2017-2018) - Merck Sharp & Dohme : lipids (2017-2018) - Vianex : lipids (2017-2018) - Bayer Healthcare : Thrombosis (2017-2018) - Servier : LIPIDS (2018) - RAFARM : LIPIDS (2018) - ELPEN : LIPIDS-THROMBOSIS (2018) - Leo Pharma : THROMBOSIS (2018) - NovaGEM CYPRUS : THROMBOSIS (2018)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2017-2018) - Medtronic : Stents (2017-2018) - Biotronik : stents (2017-2018) - Terumo Inc : stents (2017-2018) - Abbott Vascular : stents (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2017-2018) - Novartis : Arterial Hypertension, Heart Failure (2017-2018) - Merck Sharp & Dohme : Atherosclerosis (2017-2018) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017-2018) - Pfizer : General Cardiology (2017-2018)
Simpson Iain A	<p>Nothing to be declared (2018)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Surgical Valves (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Touyz Rhian	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : antihypertensive drugs (2017-2018) - Alnylam : antihypertensive drugs (2017-2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - British Heart Foundation : Hypertension research (2017-2018) - Medical Research Council, UK : Hypertension research (2017-2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American Heart Association International Society of Hypertension British Irish Hypertension Society (2017-2018)
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) - CSL Behring : Invasive Cardiology (2018) - Polares Medical : Invasive Cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) - Abbott : General Cardiology (2017-2018) - Boston Scientific : General Cardiology (2017-2018) - Edwards Lifesciences : General Cardiology (2018) - Medtronic : General Cardiology (2018) - Biotronik : General Cardiology (2018) - Amgen Inc : General Cardiology (2018) - Bristol Myers Squibb : General Cardiology (2018) - Bayer AG : General Cardiology (2018) - Sinomed : General Cardiology (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017-2018)